180 related articles for article (PubMed ID: 9310250)
41. Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy.
Parsons SL; Watson SA; Collins HM; Griffin NR; Clarke PA; Steele RJ
Br J Cancer; 1998 Dec; 78(11):1495-502. PubMed ID: 9836483
[TBL] [Abstract][Full Text] [Related]
42. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.
Lengyel E; Schmalfeldt B; Konik E; Späthe K; Härting K; Fenn A; Berger U; Fridman R; Schmitt M; Prechtel D; Kuhn W
Gynecol Oncol; 2001 Aug; 82(2):291-8. PubMed ID: 11531282
[TBL] [Abstract][Full Text] [Related]
43. Localization of matrix metalloproteinases-1, -2, and -9 and tissue inhibitor of metalloproteinase-2 in interstitial lung diseases.
Fukuda Y; Ishizaki M; Kudoh S; Kitaichi M; Yamanaka N
Lab Invest; 1998 Jun; 78(6):687-98. PubMed ID: 9645759
[TBL] [Abstract][Full Text] [Related]
44. Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2 and -3) in oral lichen planus, dysplasia, squamous cell carcinoma and lymph node metastasis.
Sutinen M; Kainulainen T; Hurskainen T; Vesterlund E; Alexander JP; Overall CM; Sorsa T; Salo T
Br J Cancer; 1998 Jun; 77(12):2239-45. PubMed ID: 9649139
[TBL] [Abstract][Full Text] [Related]
45. Secretion of matrix metalloproteinase-2, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinases into the intrauterine compartments during early pregnancy.
Riley SC; Leask R; Chard T; Wathen NC; Calder AA; Howe DC
Mol Hum Reprod; 1999 Apr; 5(4):376-81. PubMed ID: 10321811
[TBL] [Abstract][Full Text] [Related]
46. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
47. Regulated expression of matrix metalloproteinases and TIMP in nephrogenesis.
Tanney DC; Feng L; Pollock AS; Lovett DH
Dev Dyn; 1998 Sep; 213(1):121-9. PubMed ID: 9733107
[TBL] [Abstract][Full Text] [Related]
48. Expression of gelatinases A and B, and TIMPs 1 and 2 during corneal wound healing.
Ye HQ; Azar DT
Invest Ophthalmol Vis Sci; 1998 May; 39(6):913-21. PubMed ID: 9579471
[TBL] [Abstract][Full Text] [Related]
49. Lipodermatosclerosis is characterized by elevated expression and activation of matrix metalloproteinases: implications for venous ulcer formation.
Herouy Y; May AE; Pornschlegel G; Stetter C; Grenz H; Preissner KT; Schöpf E; Norgauer J; Vanscheidt W
J Invest Dermatol; 1998 Nov; 111(5):822-7. PubMed ID: 9804345
[TBL] [Abstract][Full Text] [Related]
50. Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis.
Goldbach-Mansky R; Lee JM; Hoxworth JM; Smith D; Duray P; Schumacher RH; Yarboro CH; Klippel J; Kleiner D; El-Gabalawy HS
Arthritis Res; 2000; 2(2):145-53. PubMed ID: 11062605
[TBL] [Abstract][Full Text] [Related]
51. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
52. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
53. Expression of matrix metalloproteinases during rat skin wound healing: evidence that membrane type-1 matrix metalloproteinase is a stromal activator of pro-gelatinase A.
Okada A; Tomasetto C; Lutz Y; Bellocq JP; Rio MC; Basset P
J Cell Biol; 1997 Apr; 137(1):67-77. PubMed ID: 9105037
[TBL] [Abstract][Full Text] [Related]
54. Tumor progression driven by pathways activating matrix metalloproteinases and their inhibitors.
Bodnar M; Szylberg Ł; Kazmierczak W; Marszalek A
J Oral Pathol Med; 2015 Jul; 44(6):437-43. PubMed ID: 25244188
[TBL] [Abstract][Full Text] [Related]
55. Expression of matrix metalloproteinases and their inhibitors in medulloblastomas and their prognostic relevance.
Ozen O; Krebs B; Hemmerlein B; Pekrun A; Kretzschmar H; Herms J
Clin Cancer Res; 2004 Jul; 10(14):4746-53. PubMed ID: 15269148
[TBL] [Abstract][Full Text] [Related]
56. Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma.
Nuovo GJ; MacConnell PB; Simsir A; Valea F; French DL
Cancer Res; 1995 Jan; 55(2):267-75. PubMed ID: 7812956
[TBL] [Abstract][Full Text] [Related]
57. Predominance of MMP-1 and MMP-2 in epiretinal and subretinal membranes of proliferative vitreoretinopathy.
Webster L; Chignell AH; Limb GA
Exp Eye Res; 1999 Jan; 68(1):91-8. PubMed ID: 9986746
[TBL] [Abstract][Full Text] [Related]
58. IL-10 inhibition of human prostate PC-3 ML cell metastases in SCID mice: IL-10 stimulation of TIMP-1 and inhibition of MMP-2/MMP-9 expression.
Stearns ME; Fudge K; Garcia F; Wang M
Invasion Metastasis; 1997; 17(2):62-74. PubMed ID: 9561025
[TBL] [Abstract][Full Text] [Related]
59. Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma.
Pennanen H; Kuittinen O; Soini Y; Turpeenniemi-Hujanen T
Eur J Haematol; 2008 Oct; 81(4):289-97. PubMed ID: 18616513
[TBL] [Abstract][Full Text] [Related]
60. Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors.
Lampert K; Machein U; Machein MR; Conca W; Peter HH; Volk B
Am J Pathol; 1998 Aug; 153(2):429-37. PubMed ID: 9708803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
